• What is TMS Therapy^®?
  • About NeuroStar TMS^®
  • NeuroStar TMS Therapy^® — Unique Mechanism of Action
  • TMS Therapy^® – A Key Role in the Treatment of Depression
• NeuroStar^® Clinical Research
  • NeuroStar TMS Therapy^® — Proven Efficacy
  • NeuroStar^® Safety
  • Scientific Publications and Presentations
• NeuroStar TMS Therapy^® System
  • NeuroStar^® System Components
  • The SenStar^® Advantage
  • TMS TrakStar™ Practice Data Management Software
  • Setting Up a NeuroStar^® Practice
  • Physician Experiences with NeuroStar^®
• NeuroStar^® Service & Support
  • NeuroStar^® University Clinical Training
  • Patient Education
  • Practice Support
  • Reimbursement Support
  • Public Relations & Local Outreach
  • StarGuard™ Field Service Solutions
  • NeuroStar^® Providers
• Reimbursement Support
  • Coding and Billing for NeuroStar TMS Therapy^®
  • NeuroStar Reimbursement Support
  • Reimbursement Support Materials
  • Coverage and Medical Policies
• NeuroStar^® Resources
  • Recent Press Coverage
  • Recent Press Releases
  • Events & Exhibits
  • Medical Education Events
  • Press Contact
• Contact Us
  • Healthcare Professional Contact Information

NeuroStar TMS Therapy^® — Proven Efficacy

Clinical Results: Randomized Controlled Trial¹

Primary diagnosis:  DSM-IV Major Depressive Disorder

• Unipolar type, non-psychotic
• Moderate to severe symptoms at baseline
• Approximately one-third of patients had a co-morbid anxiety disorder (OCD excluded)

Antidepressant Treatment History (Indicated Population)

• Average number of antidepressant medication trials in current episode = 4 (range: 1 to 23 attempts)
• Majority of treatment attempts were unable to achieve adequate dose (minimum labeled dose) and duration (at least 4 weeks) of treatment due to intolerance
• In the indicated patient population, all patients failed to achieve satisfactory benefit from one antidepressant medication at an adequate dose and duration in the current episode

NeuroStar Randomized Controlled Trial Key Outcome Measure (Indicated Population) – Change Score in Montgomery Asberg Depression Rating Scale (MADRS)

In this controlled clinical trial, patients received an average reduction in their depression symptom score of 22.1% with active NeuroStar TMS Therapy as compared to a 9% average reduction in patients receiving inactive (sham) treatment.  Statistical significance in favor of active NeuroStar TMS was observed as early as 2 weeks after treatment and at 4 and 6 weeks.

Treatment Utilization and Outcomes Study²

Patient Population & Sites

• 307 (acute phase) evaluable unipolar, non-psychotic MDD patients in post-market use
• 42 sites comprised of institutions and private practice

Study Duration

• 2 years for entire study
• Acute course as prescribed
• 12 month follow-up

The results of the open-label Outcomes study are consistent with prior open-label outcomes for NeuroStar TMS Therapy, in which 1 in 2 patients suffering with depression improved significantly, and 1 in 3 patients were completely free of depression symptoms after six weeks of treatment.³

View NeuroStar TMS Therapy Safety Data

1. O’Reardon, J. P., H. B. Solvason, et al. (2007). “Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression:  A Multisite Randomized Controlled Trial.” Biol Psychiatry 62(11): 1208-1216.
2. Neuronetics, Inc. (data on file, 2012)
3. Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharm Bull. 2009, 42(2): 5-38.